Female Fertility: The Evidence-Based Supplement Protocol

← Back to articles

Female fertility is dominated by factors that no supplement can change: age, ovarian reserve, tubal patency, the partner's sperm, and conditions such as PCOS or endometriosis. For diagnosed infertility, medical care — ovulation induction, IUI, IVF — is the intervention with real effect sizes. Supplements occupy a narrower, honest role: preventing one specific birth defect, correcting nutrient deficiencies, and, more marginally, nudging oocyte and ovulation outcomes. Below, the supplements are ordered by how strong the evidence actually is. Only one of them has the kind of evidence that justifies recommending it to nearly everyone trying to conceive.

Folic acid (or 5-MTHF), 400–800 mcg daily — the one clear win

This is the strongest evidence-based supplement intervention in all of reproductive medicine, and it is not about getting pregnant — it is about the health of the pregnancy. In the landmark MRC Vitamin Study, a randomized, double-blind, placebo-controlled trial of 1,817 high-risk women across seven countries, periconceptional folic acid reduced the recurrence of neural tube defects (spina bifida, anencephaly) by 72% (relative risk 0.28, 95% CI 0.12–0.71). A Cochrane review of randomized trials confirms a clear protective effect against neural tube defects. The grade here is strong (A). Practical translation: start a prenatal supplement supplying at least 400 mcg of folate one to three months before conception and continue through the first trimester. Women with a prior affected pregnancy or on certain medications may be advised a higher dose by their clinician. Folic acid and the methylated form (5-MTHF) both raise folate status; for most people the cheaper folic acid is well validated, and the practical case for 5-MTHF is modest.

CoQ10 (ubiquinol or ubiquinone), ~30–600 mg daily — modest, mainly for older or low-reserve women

Ovarian mitochondrial function declines with age, and CoQ10 is the most-studied antioxidant aimed at this problem. A 2024 systematic review and meta-analysis of 20 randomized trials in women with ovarian aging found that antioxidants — with CoQ10 standing out from melatonin, inositol, and vitamins — increased the number of retrieved oocytes and high-quality embryos and modestly raised clinical pregnancy rates, with benefit most evident in women with diminished ovarian reserve, especially those under 35. A separate network meta-analysis of poor-responder IVF found CoQ10 (alongside DHEA) raised clinical pregnancy odds versus control. But in the cleanest single randomized trial — 169 young poor-responders — CoQ10 pre-treatment improved oocyte and embryo measures, yet the difference in clinical pregnancy and live birth did not reach statistical significance. So the honest grade is moderate–weak (C): real signal on intermediate endpoints, not yet proven on take-home-baby rates. Typical regimens run 60–90 days before an IVF cycle; doses in trials ranged widely, and the meta-analysis hinted lower doses performed at least as well.

Myo-inositol, 2–4 g daily — for PCOS-related anovulation

For women whose infertility stems from PCOS-related anovulation, myo-inositol is a reasonable, low-risk adjunct. An umbrella review of randomized-trial meta-analyses graded the evidence that inositol stimulates ovulation in subfertile women with PCOS as moderate certainty, and a 2025 meta-analysis of IVF cohorts found myo-inositol improved mature (MII) oocyte and fertilization rates, particularly in PCOS. The important caveat: a dedicated Cochrane review concluded that, on the outcomes that matter most — live birth and clinical pregnancy — the evidence remains very low certainty and genuinely uncertain. Grade: moderate for ovulation, weak/uncertain for live birth (C). Many protocols add D-chiro inositol in a 40:1 myo-to-D-chiro ratio, though the incremental evidence for the combination over myo-inositol alone is thin.

Vitamin D — correct a deficiency, do not chase a target

Low vitamin D status is associated with poorer IVF fertilization in cohort data, and umbrella reviews list vitamin D among nutrients linked to higher clinical pregnancy in assisted reproduction — but only at very low certainty, and randomized trials are small and inconsistent. The defensible use is narrow: if blood testing shows deficiency, repletion is sensible general health advice. There is no good evidence that pushing an already-normal level higher improves fertility. Grade: weak (C/D); reasonable to correct deficiency, not a fertility booster.

DHEA — diminished ovarian reserve only, and only with a specialist

DHEA is an androgen precursor studied as IVF pre-treatment in women with diminished ovarian reserve or poor response. The network meta-analysis above found DHEA raised clinical pregnancy odds in poor responders, and a fertility overview review rated the evidence for DHEA in this specific group as moderate quality. This is genuinely a prescription-territory decision: DHEA converts to androgens and can cause acne and hirsutism, and it is inappropriate for women with normal ovarian reserve or PCOS. Grade: moderate, but narrow (C) — use only under reproductive-endocrinology supervision, not self-directed.

What is overhyped — and what to avoid

The broad "antioxidants improve female fertility" claim is weaker than the marketing suggests. The Cochrane review of antioxidants for female subfertility, pooling 63 trials in 7,760 women, rated the evidence for any live-birth benefit as very low certainty — and several of its included trials have since been retracted or flagged with concerns, a reminder that this literature is thin and unreliable. A 2024 umbrella review of supplements for female infertility reached the same bottom line: the available evidence is insufficient to recommend nutrient supplements to improve fertility, though they do not appear to cause significant harm. So treat multi-ingredient "fertility blend" pills as low-yield. On safety: avoid high-dose vitamin A/retinol and liver products around conception and in early pregnancy (teratogenic risk), and avoid herbal products including St. John's Wort, kava, ginkgo, and high-dose ginseng in the conception window. Discuss any herb, including vitex (chasteberry), with your clinician before starting ovulation induction.

How to run a sane protocol

For nearly everyone trying to conceive, the supplement story is short: take a prenatal supplying at least 400 mcg of folate, starting one to three months ahead — that is the part with strong evidence. Correct a vitamin D deficiency if testing shows one. If you are over 35, have diminished ovarian reserve, or are heading into IVF, CoQ10 for 60–90 days is a low-risk add-on with modest, intermediate-endpoint support. If your infertility is PCOS-related anovulation, myo-inositol is a reasonable adjunct. Reserve DHEA for diminished-reserve cases managed by a specialist. Everything else is optional at best. The dominant lever in female fertility remains age and timely medical care; supplements operate at the margins, and being honest about that is the most useful thing this page can do.